BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System
Pharmaceuticals · 18.08.2026 · 19 (8) · 1305
DOI: 10.3390/ph19081305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 18.08.2026. Verfasst von Francisco Arias-Aragón und 21 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), 06080 Badajoz, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Health Carlos III, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background/Objectives: Pharmacogenetics (PGx) may improve drug safety and effectiveness, but its integration into routine care remains heterogeneous across the Spanish National Health System (NHS). This article presents BioFRAM PGx, a multicentre implementation framework that defines the methodological and operational basis for subsequent observational validation in cardiovascular and mental-health care settings.
Methods
The framework was developed by healthcare centres from eight Spanish Autonomous Communities through a structured review of PharmGKB/ClinPGx clinical annotations, CPIC and DPWG guidelines, and national regulatory resources. Gene–drug pairs were prioritized according to clinical actionability, therapeutic relevance, applicability to the Spanish population, and analytical feasibility. BioFRAM PGx defines a panel of seven pharmacogenes and 35 drugs, standardized genotyping and phenotype-assignment procedures, pharmacovigilance and clinical variables, healthcare-resource measures, and centralized data management. The proposed non-interventional validation phase includes adults receiving at least one selected drug in hospital or primary-care settings, with a minimum six-month follow-up. PGx results are not returned to clinicians and do not modify treatment. Its primary objective is to assess the predictive value of PGx genotyping for adverse drug reactions (ADRs); secondary objectives include ADR incidence and implementation feasibility.
Results
The main outputs are the proposed multicentre observational design, the prioritized gene–drug panel, harmonized analytical and pharmacovigilance workflows, standardized data domains, and a centralized data-management strategy. No patient-level clinical, implementation, or economic outcomes are presented.
Conclusions
BioFRAM PGx provides a structured multicentre framework for harmonizing pharmacogenetic procedures across the Spanish NHS. Its clinical effectiveness, influence on prescribing, scalability, and economic outcomes remain to be assessed in subsequent studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), 06080 Badajoz, Spain.
- Pharmacogenetic and Personalised Medicine Unit, Extremadura Health Service, Badajoz University Hospital, Extremadura University, 06080 Badajoz, Spain.
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Pharmacology Department, Faculty of Medicine, Instituto de Investigación Sanitaria la Princesa (IIS-Princesa), Universidad Autónoma de Madrid, 280…
- Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, Fundació Clínic per a la Recerca Biomèdica (FC…
- Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, Fundació de Recerca Clínic Barcelona-Institut…
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
ORCID-Profile: Francisco Arias-Aragón, Carmen Mata-Martín, Jesús Novalbos, Francisco Abad-Santos, Mar Hernaez, David Hansoe Heredero-Jung, Almudena Gil-Rodriguez, Enrique G Zucchet, María José Herrero, José Manuel Dodero-Anillo
Förderung
- Institute of Health Carlos III
- Instituto de Salud Carlos III
Zitieren
APA
Arias-Aragón, F., Mata-Martín, C., Sánchez-Redondo, A., Novalbos, J., Seguido, M. Á., Abad-Santos, F., Hernaez, M., Brunet, M., Heredero-Jung, D. H., Sota-Pérez, A., Isidoro-García, M., Gil-Rodriguez, A., Barral-Raña, A., Maroñas, O., Pasquini, G. G. O., Zucchet, E. G., Herrero, M. J., Dodero-Anillo, J. M., Máñez, A. A., …, & On Behalf Of The BioFRAM PGx Consortium (2026). BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System. Pharmaceuticals, 19(8), 1305. https://doi.org/10.3390/ph19081305
Vancouver
Arias-Aragón F, Mata-Martín C, Sánchez-Redondo A, Novalbos J, Seguido MÁ, Abad-Santos F, et al. BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System. Pharmaceuticals. 2026;19(8):1305. doi:10.3390/ph19081305
BibTeX
@article{AriasAragn2026,
author = {Arias-Aragón, Francisco and Mata-Martín, Carmen and Sánchez-Redondo, Alba and Novalbos, Jesús and Seguido, Miguel Ángel and Abad-Santos, Francisco and Hernaez, Mar and Brunet, Mercè and Heredero-Jung, David Hansoe and Sota-Pérez, Alejandro de la and Isidoro-García, María and Gil-Rodriguez, Almudena and Barral-Raña, Alba and Maroñas, Olalla and Pasquini, Gladys Guadalupe Olivera and Zucchet, Enrique G and Herrero, María José and Dodero-Anillo, José Manuel and Máñez, Alicia Alba and Pedrosa-Martínez, María José and Llerena, Adrián and On Behalf Of The BioFRAM PGx Consortium},
title = {BioFRAM PGx, an Implementation Proposal for Pharmacogenetics in the Spanish National Health System},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1305},
doi = {10.3390/ph19081305}
}
EUVIMED